Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) have been given an average recommendation of "Buy" by the six brokerages that are covering the stock, Marketbeat.com reports. Five analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $25.20.
A number of brokerages recently weighed in on ATXS. Evercore ISI upgraded Astria Therapeutics to a "strong-buy" rating in a report on Wednesday, August 14th. Wedbush reaffirmed an "outperform" rating and set a $22.00 price target on shares of Astria Therapeutics in a research note on Tuesday, August 13th. HC Wainwright reissued a "buy" rating and issued a $16.00 price objective on shares of Astria Therapeutics in a research note on Friday, September 27th. Oppenheimer upped their target price on shares of Astria Therapeutics from $25.00 to $26.00 and gave the company an "outperform" rating in a research report on Tuesday, August 13th. Finally, TD Cowen began coverage on Astria Therapeutics in a research report on Monday, July 29th. They issued a "buy" rating and a $35.00 price target for the company.
Check Out Our Latest Analysis on ATXS
Astria Therapeutics Stock Performance
Shares of NASDAQ ATXS traded up $0.07 during midday trading on Wednesday, hitting $12.06. 216,955 shares of the company traded hands, compared to its average volume of 636,392. Astria Therapeutics has a 12-month low of $4.26 and a 12-month high of $16.90. The stock has a 50-day moving average price of $11.57 and a 200 day moving average price of $10.49. The firm has a market cap of $662.25 million, a P/E ratio of -5.17 and a beta of 0.71.
Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last announced its quarterly earnings data on Monday, August 12th. The biotechnology company reported ($0.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.05). As a group, equities analysts expect that Astria Therapeutics will post -1.72 earnings per share for the current year.
Institutional Trading of Astria Therapeutics
A number of hedge funds and other institutional investors have recently bought and sold shares of ATXS. SG Americas Securities LLC acquired a new position in Astria Therapeutics in the 3rd quarter valued at $155,000. Cubist Systematic Strategies LLC acquired a new stake in Astria Therapeutics in the 2nd quarter valued at about $2,561,000. Nantahala Capital Management LLC purchased a new position in shares of Astria Therapeutics during the 2nd quarter worth approximately $6,142,000. Susquehanna Fundamental Investments LLC purchased a new position in Astria Therapeutics during the second quarter worth $400,000. Finally, Millennium Management LLC lifted its position in shares of Astria Therapeutics by 13.5% in the second quarter. Millennium Management LLC now owns 1,842,063 shares of the biotechnology company's stock valued at $16,763,000 after acquiring an additional 218,518 shares in the last quarter. 98.98% of the stock is currently owned by institutional investors and hedge funds.
Astria Therapeutics Company Profile
(
Get Free ReportAstria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.
Featured Stories
Before you consider Astria Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astria Therapeutics wasn't on the list.
While Astria Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.